Spero Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M |
| Research and development | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M |
| Operating expenses | $60.5M | $121.3M | $82.3M | $95.7M | $106.2M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M | -$88.0M |
| Pretax income | $8.8M | -$68.6M | $25.4M | -$46.4M | -$89.8M |
| Income tax expense | $261,000 | $0 | $2.6M | $0 | $0 |
| Net income | $8.6M | -$68.6M | $22.8M | -$46.4M | -$89.8M |
| Balance Sheet | |||||
| Cash and equivalents | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M |
| Current assets | $67.3M | $107.3M | $131.2M | $113.6M | $157.9M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Current liabilities | $8.9M | $49.1M | $37.2M | $21.6M | $18.7M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M |
| Stockholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.6M | -$23.4M | -$33.0M | -$7.7M | -$64.3M |
| Depreciation and amortization | $0 | $2,000 | $367,000 | $869,000 | $646,000 |
| Stock-based compensation | $4.3M | $7.8M | $7.9M | $9.1M | $9.4M |
| Impairments | $587,000 | $0 | $5.3M | $635,000 | $0 |
Shares outstanding 57.9M · Free float 75.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.